특발성 혈소판 감소성 자반증 - 시장 인사이트, 역학 및 시장 예측(2034년)

Idiopathic Thrombocytopenic Purpura - Market Insight, Epidemiology, and Market Forecast - 2034

US $ 7,950 ￦ 11,502,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,925 ￦ 17,254,000

PDF (2-3 User License)

PDF 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 15,900 ￦ 23,005,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 23,850 ￦ 34,508,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

이 보고서는 특발성 혈소판 감소성 자반증의 주요 7개 시장(미국, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본)을 조사 분석하여 각 지역의 시장 규모, 현재 치료법, 미충족 수요, 새로운 치료법 등에 대한 정보를 제공합니다.

목차

제1장 주요 인사이트

제2장 특발성 혈소판 감소성 자반증 주요 요약

제3장 특발성 혈소판 감소성 자반증 경쟁 정보 분석

제4장 특발성 혈소판 감소성 자반증 : 시장 개요

• 특발성 혈소판 감소성 자반증 전체 시장 점유율 분포(2020년)
• 특발성 혈소판 감소성 자반증 전체 시장 점유율 분포(2034년)

제5장 특발성 혈소판 감소성 자반증 : 질환 배경과 개요

• 소개
• 징조와 증상
• 병태생리학
• 위험인자
• 진단

제6장 환자 여정

제7장 특발성 혈소판 감소성 자반증 역학과 환자 인구

• 역학의 주요 조사 결과
• 가정과 근거 : 주요 7개 시장
• 역학 시나리오 : 주요 7개 시장
  • 주요 7개 시장의 특발성 혈소판 감소성 자반증 역학 시나리오(2020-2034년)
• 미국의 역학
  • 미국의 특발성 혈소판 감소성 자반증 역학 시나리오(2020-2034년)
• 유럽 5개국의 역학 : 국가별
  • 독일의 역학
  • 프랑스의 역학
  • 이탈리아의 역학
  • 스페인의 역학
  • 영국의 역학
  • 일본의 역학

제8장 치료 알고리즘, 현재 치료, 의료 행위

• 특발성 혈소판 감소성 자반증 치료와 관리
• 특발성 혈소판 감소성 자반증 치료 알고리즘

제9장 미충족 수요

제10장 특발성 혈소판 감소성 자반증 치료의 주요 평가 항목

제11장 출시된 제품

제12장 새로운 치료법

제13장 특발성 혈소판 감소성 자반증 : 주요 7개 시장 분석

• 주요 조사 결과
• 주요 7개 시장의 특발성 혈소판 감소성 자반증 시장 규모
• 주요 7개 시장의 특발성 혈소판 감소성 자반증 시장 규모 : 치료법별

제14장 속성 분석

제15장 주요 7개 시장 : 시장 전망

• 미국 : 시장 규모
  • 미국의 특발성 혈소판 감소성 자반증 전체 시장 규모
  • 미국의 특발성 혈소판 감소성 자반증 시장 규모 : 치료법별
• 유럽 5개국 : 시장 규모와 전망
• 독일의 시장 규모
  • 독일의 특발성 혈소판 감소성 자반증 전체 시장 규모
  • 독일의 특발성 혈소판 감소성 자반증 시장 규모 : 치료법별
• 프랑스의 시장 규모
• 이탈리아의 시장 규모
• 스페인의 시장 규모
• 영국의 시장 규모
  • 영국의 특발성 혈소판 감소성 자반증 전체 시장 규모
  • 영국의 특발성 혈소판 감소성 자반증 시장 규모 : 치료법별
• 일본 시장 전망
  • 일본의 시장 규모

제16장 특발성 혈소판 감소성 자반증 액세스와 상환 개요

제17장 KOL의 견해

제18장 시장 성장 촉진요인

제19장 시장 장벽

제20장 부록

제21장 DelveInsight의 서비스 내용

제22장 면책사항

제23장 DelveInsight 소개

ksm

영문 목차

영문목차

DelveInsight's "Idiopathic Thrombocytopenic Purpura - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Idiopathic Thrombocytopenic Purpura, historical and forecasted epidemiology as well as the Idiopathic Thrombocytopenic Purpura market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Idiopathic Thrombocytopenic Purpura market report provides current treatment practices, emerging drugs, Idiopathic Thrombocytopenic Purpura market share of the individual therapies, current and forecasted Idiopathic Thrombocytopenic Purpura market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Idiopathic Thrombocytopenic Purpura treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Idiopathic Thrombocytopenic Purpura Disease Understanding and Treatment Algorithm

The DelveInsight Idiopathic Thrombocytopenic Purpura market report gives a thorough understanding of the Idiopathic Thrombocytopenic Purpura by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Idiopathic Thrombocytopenic Purpura.

Treatment

It covers the details of conventional and current medical therapies available in the Idiopathic Thrombocytopenic Purpura market for the treatment of the condition. It also provides Idiopathic Thrombocytopenic Purpura treatment algorithms and guidelines in the United States, Europe, and Japan.

Idiopathic Thrombocytopenic Purpura Epidemiology

The Idiopathic Thrombocytopenic Purpura epidemiology division provide insights about historical and current Idiopathic Thrombocytopenic Purpura patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Idiopathic Thrombocytopenic Purpura epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Idiopathic Thrombocytopenic Purpura Epidemiology

The epidemiology segment also provides the Idiopathic Thrombocytopenic Purpura epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Idiopathic Thrombocytopenic Purpura Drug Chapters

Drug chapter segment of the Idiopathic Thrombocytopenic Purpura report encloses the detailed analysis of Idiopathic Thrombocytopenic Purpura marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Idiopathic Thrombocytopenic Purpura clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Idiopathic Thrombocytopenic Purpura treatment.

Idiopathic Thrombocytopenic Purpura Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Idiopathic Thrombocytopenic Purpura treatment.

Idiopathic Thrombocytopenic Purpura Market Outlook

The Idiopathic Thrombocytopenic Purpura market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Idiopathic Thrombocytopenic Purpura market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Idiopathic Thrombocytopenic Purpura market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Idiopathic Thrombocytopenic Purpura market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Idiopathic Thrombocytopenic Purpura market in 7MM.

The United States Market Outlook

This section provides the total Idiopathic Thrombocytopenic Purpura market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Idiopathic Thrombocytopenic Purpura market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Idiopathic Thrombocytopenic Purpura market size and market size by therapies in Japan is also mentioned.

Idiopathic Thrombocytopenic Purpura Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Idiopathic Thrombocytopenic Purpura market or expected to get launched in the market during the study period 2020-2034. The analysis covers Idiopathic Thrombocytopenic Purpura market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Idiopathic Thrombocytopenic Purpura Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Idiopathic Thrombocytopenic Purpura key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Idiopathic Thrombocytopenic Purpura emerging therapies.

Reimbursement Scenario in Idiopathic Thrombocytopenic Purpura

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Idiopathic Thrombocytopenic Purpura domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Idiopathic Thrombocytopenic Purpura market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Idiopathic Thrombocytopenic Purpura Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Idiopathic Thrombocytopenic Purpura, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Idiopathic Thrombocytopenic Purpura epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Idiopathic Thrombocytopenic Purpura are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Idiopathic Thrombocytopenic Purpura market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Idiopathic Thrombocytopenic Purpura market

Report Highlights:

• In the coming years, Idiopathic Thrombocytopenic Purpura market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Idiopathic Thrombocytopenic Purpura R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Idiopathic Thrombocytopenic Purpura. Launch of emerging therapies will significantly impact the Idiopathic Thrombocytopenic Purpura market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Idiopathic Thrombocytopenic Purpura
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Idiopathic Thrombocytopenic Purpura Report Insights

• Patient Population
• Therapeutic Approaches
• Idiopathic Thrombocytopenic Purpura Pipeline Analysis
• Idiopathic Thrombocytopenic Purpura Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Idiopathic Thrombocytopenic Purpura Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Idiopathic Thrombocytopenic Purpura Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Idiopathic Thrombocytopenic Purpura Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Idiopathic Thrombocytopenic Purpura market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Idiopathic Thrombocytopenic Purpura total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Idiopathic Thrombocytopenic Purpura market size during the forecast period (2024-2034)?
• At what CAGR, the Idiopathic Thrombocytopenic Purpura market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the Idiopathic Thrombocytopenic Purpura market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Idiopathic Thrombocytopenic Purpura market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Idiopathic Thrombocytopenic Purpura?
• What is the historical Idiopathic Thrombocytopenic Purpura patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Idiopathic Thrombocytopenic Purpura in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Idiopathic Thrombocytopenic Purpura?
• Out of all 7MM countries, which country would have the highest prevalent population of Idiopathic Thrombocytopenic Purpura during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Idiopathic Thrombocytopenic Purpura treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Idiopathic Thrombocytopenic Purpura in the USA, Europe, and Japan?
• What are the Idiopathic Thrombocytopenic Purpura marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Idiopathic Thrombocytopenic Purpura?
• How many therapies are developed by each company for Idiopathic Thrombocytopenic Purpura treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Idiopathic Thrombocytopenic Purpura treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Idiopathic Thrombocytopenic Purpura therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Idiopathic Thrombocytopenic Purpura and their status?
• What are the key designations that have been granted for the emerging therapies for Idiopathic Thrombocytopenic Purpura?
• What are the global historical and forecasted market of Idiopathic Thrombocytopenic Purpura?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Idiopathic Thrombocytopenic Purpura market
• To understand the future market competition in the Idiopathic Thrombocytopenic Purpura market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Idiopathic Thrombocytopenic Purpura in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Idiopathic Thrombocytopenic Purpura market
• To understand the future market competition in the Idiopathic Thrombocytopenic Purpura market

Table of Contents

1. Key Insights

2. Executive Summary of Idiopathic Thrombocytopenic Purpura

3. Competitive Intelligence Analysis for Idiopathic Thrombocytopenic Purpura

4. Idiopathic Thrombocytopenic Purpura: Market Overview at a Glance

• 4.1. Idiopathic Thrombocytopenic Purpura Total Market Share (%) Distribution in 2020
• 4.2. Idiopathic Thrombocytopenic Purpura Total Market Share (%) Distribution in 2034

5. Idiopathic Thrombocytopenic Purpura: Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Idiopathic Thrombocytopenic Purpura Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Idiopathic Thrombocytopenic Purpura Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. Idiopathic Thrombocytopenic Purpura Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Idiopathic Thrombocytopenic Purpura Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Idiopathic Thrombocytopenic Purpura Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Idiopathic Thrombocytopenic Purpura Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Idiopathic Thrombocytopenic Purpura Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Idiopathic Thrombocytopenic Purpura Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Idiopathic Thrombocytopenic Purpura Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Idiopathic Thrombocytopenic Purpura Treatment and Management
• 8.2. Idiopathic Thrombocytopenic Purpura Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Idiopathic Thrombocytopenic Purpura Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. Idiopathic Thrombocytopenic Purpura: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Idiopathic Thrombocytopenic Purpura Market Size in 7MM
• 13.3. Idiopathic Thrombocytopenic Purpura Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Idiopathic Thrombocytopenic Purpura Total Market Size in the United States
  • 15.1.2. Idiopathic Thrombocytopenic Purpura Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Idiopathic Thrombocytopenic Purpura Total Market Size in Germany
  • 15.3.2. Idiopathic Thrombocytopenic Purpura Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Idiopathic Thrombocytopenic Purpura Total Market Size in France
  • 15.4.2. Idiopathic Thrombocytopenic Purpura Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Idiopathic Thrombocytopenic Purpura Total Market Size in Italy
  • 15.5.2. Idiopathic Thrombocytopenic Purpura Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Idiopathic Thrombocytopenic Purpura Total Market Size in Spain
  • 15.6.2. Idiopathic Thrombocytopenic Purpura Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Idiopathic Thrombocytopenic Purpura Total Market Size in the United Kingdom
  • 15.7.2. Idiopathic Thrombocytopenic Purpura Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Idiopathic Thrombocytopenic Purpura Total Market Size in Japan
  • 15.8.3. Idiopathic Thrombocytopenic Purpura Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Idiopathic Thrombocytopenic Purpura

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.

관련자료